|Bid||43.50 x 4000|
|Ask||43.50 x 1100|
|Day's Range||43.25 - 43.90|
|52 Week Range||41.45 - 56.32|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||7.97|
|Earnings Date||May 01, 2023 - May 05, 2023|
|Forward Dividend & Yield||1.64 (3.75%)|
|Ex-Dividend Date||Jan 26, 2023|
|1y Target Est||52.81|
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The pharmaceutical giant gained an analyst's buy recommendation but its technical signals are lackluster at best.
Last year was a stellar one for Pfizer (NYSE: PFE). In January, Pfizer announced not only its latest earnings results but also a forecast for 2023, which tells investors what they already knew was inevitable: a sharp decline in sales is coming. A decline in revenue isn't a shock given that concerns surrounding COVID appear to be fading, but the reason for the soft numbers isn't entirely due to demand.